RxDoctor Payments Data

Amanda McKee

Family · Mount Vernon, ILNPI 1194740571

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $196,463 of the $242,472 with a category attached, or 81.0%. Amgen accounts for 99.9% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $73,554 and has fallen 65.6% since, to $25,318 in 2025. Among family clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$242,472in general payments, 2019–2025

Across 538 payments — averaging $450.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$242K
  • UCB, Inc.$124
  • Pacira Therapeutics, Inc.$69
  • Pacira Pharmaceuticals Incorporated$30
  • Ferring Pharmaceuticals Inc.$26
  • Radius Health, Inc.$14

What the payments were for

  • Consulting fees$7,1993%
  • Speaking & faculty fees$196,46381%
  • Travel & lodging$31,86613%
  • Food & beverage$6,8813%
  • Education$640%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$242,472 in reported general payments places this provider in the 95th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$6,638,914
Medicare patients
1,372
Services billed
455,189

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProliaDenosumab11$19,346
Calcitriol319$4,214
Alendronate Sodium198$880
Tramadol Hcl78$651
Vitamin D2Ergocalciferol (Vitamin D2)48$525
Gabapentin19$391
Ibandronate Sodium13$137
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen11$86

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia$242,209$19,34611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,941 family providers in Illinois.

Other family in Mount Vernon

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →